Wockhardt informs about press release

16 Mar 2022 Evaluate

Wockhardt has informed that it enclosed a Press Release titled ‘National Institutes of Health (NIH), USA to conduct human Phase 1 trial of Wockhardt’s novel once-a-day MDR Gram-negative antibiotic WCK 6777’.

The above information is a part of company’s filings submitted to BSE.

Wockhardt Share Price

1435.00 -1.95 (-0.14%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×